Useful predictors of progression‐free survival for Japanese patients with LATITUDE‐high‐risk metastatic castration‐sensitive prostate cancer who received upfront abiraterone acetate-Reference-Cited by-同舟云学术

Useful predictors of progression‐free survival for Japanese patients with LATITUDE‐high‐risk metastatic castration‐sensitive prostate cancer who received upfront abiraterone acetate

Published:2021-12-04 Issue: Volume: Page:
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int. J. Urol.

Author:

Takahara Kiyoshi¹^ORCID,Naiki Taku²^ORCID,Ito Toshiki³,Nakane Keita⁴,Koie Takuya⁴^ORCID,Yasui Takahiro²,Miyake Hideaki³,Shiroki Ryoichi¹

Affiliation:

1. Department of Urology School of Medicine Fujita Health University ToyoakeJapan

2. Department of Nephrology Nagoya City University Graduate School of Medical Sciences NagoyaJapan

3. Department of Urology Hamamatsu University School of Medicine Hamamatsu Japan

4. Department of Urology Gifu University Gifu Japan

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.14754

Reference26 articles.

1. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

2. Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)

3. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

4. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer

5. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive Factors of Abiraterone Response in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer;Journal of Urologic Oncology;2023-11-30

2. Trends in the Use of Second-Generation Androgen Receptor Axis Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer and Clinical Factors Predicting Biological Recurrence;Diagnostics;2023-05-08

3. Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients;World Journal of Urology;2022-11-04

4. Effects of apalutamide dose reduction on skin‐related adverse events in patients with advanced prostate cancer: A multicenter retrospective study;The Prostate;2022-10-31

5. Humoral response after SARS-CoV-2 mRNA vaccination in patients with prostate cancer using steroids;Urologic Oncology: Seminars and Original Investigations;2022-10